Skip To Main Content
Kenji Morimoto on Muck Rack

Kenji Morimoto

As seen in: Bottom Line, Nature, The Guardian, Wiley Online Library, Frontiers, Yahoo Style Canada, AOL UK, Pan Macmillan, delicious. (UK), Olive Magazine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kenji

Contact Kenji, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA)

|
By Kenji Morimoto, Junji Uchino, Makoto Hibino
| Wiley Online Library Verified
1 Introduction Lung cancer is one of the leading causes of cancer-related mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for the majority of cases [1]. Despite recent advances in systemic therapy, the prognosis for patients with advanced NSCLC has historically been poor.
Open in Who Shared Issue with article?

Kenji Morimoto’s recipes for asparagus kimchi

|
By Kenji Morimoto
| Yahoo Style Canada Verified
Kenji Morimoto's asparagus kimchi tart.Photograph: Yuki Sugiura/The Guardian. Food styling: Tamara Vos. Prop styling: Rachel Vere. Food styling assistant: Georgia Rudd. (Photograph: Yuki Sugiura/The Guardian. Food styling: Tamara Vos. Prop styling: Rachel Vere. Food styling assistant: Georgia Rudd.) Spring always reminds me of the diversity of kimchi.
Open in Who Shared View Duplicates (6) Issue with article?

AXL–SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers

|
By Masaki Ishida, Tadaaki Yamada, Yuki Katayama, Hayato Kawachi, Ryo Sawada, Ryota Nakamura, Yohei Matsui, Kenji Morimoto, Mano Horinaka, Toshiyuki Sakai, Tomoki Sakakida, Toshifumi Doi, Kazuo Yasumoto, Yasuhiro Goto, Naoki Furuya, Hirokazu Taniguchi, Hirokazu Ogino, Yusuke Chihara, Koji Fukuda, Hiroaki Taniguchi, Seiji Yano, Shinsaku Tokuda, Koichi Takayama, Soichi Hirai, Keisuke Onoi, Aosa Nakamura-Sasada, Nakano Takayuki, Hisanori Uehara
| Nature Verified
Abstract Human epidermal growth factor receptor 2 (HER2)-tyrosine kinase inhibitors (TKIs) are being developed for the treatment of patients with HER2-aberrant lung and gastric cancers. However, achieving complete tumor remission remains challenging. Here, we investigated the molecular mechanisms underlying adaptive resistance to HER2-TKIs in HER2-aberrant tumor cells in order to devise strategies to prevent the emergence of drug-tolerant cells.
Open in Who Shared Issue with article?
See all 27 licensed articles (37 Total)